Status: Not yet recruiting
A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)
This retrospective real-world study aims to evaluate the efficacy and safety of anlotinib hydrochloride combined with immunotherapy as maintenance therapy following standard chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC).The study population consists of treatment-naïve ES-SCLC patients who did not progress after induction chemoimmunotherapy and subsequently received maintenance therapy with anlotinib plus immunotherapy. The primary objectives are progression-free survival (PFS)，overall survival (OS) , and safety.
Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Yong FangUpdated: Jul 8, 2025
Eligibility criteria
Male or female patients aged 18 years or older; [+6]
Patients with limited-stage SCLC who previously received chemotherapy and underw... [+5]